Aeterna Zentaris (AEZS) 0.60 $AEZS
SHAREHOLDER ALERT: LEVI & KORSINSKY, LLP Notifies Investors of Class Action Against Aeterna Zentaris Inc. and Its Board of Directors and a Lead Plaintiff Deadline of January 12, 2015 -- AEZS
GlobeNewswire - Thu Dec 11, 3:10PM CST
Levi & Korsinsky announces that a class action lawsuit has been commenced in the United States District Court for the District of New Jersey on behalf of investors who purchased Aeterna Zentaris Inc. ("Aeterna Zentaris" or the "Company"
(Nasdaq:AEZS) securities between October 18, 2012 and November 5, 2014.
AEZS: 0.60 (+0.03)
INVESTOR ALERT: Glancy Binkow & Goldberg LLP Reminds Investors of the Lead Plaintiff Deadline in the Class Action Lawsuit Against Aeterna Zentaris Inc.
Business Wire - Thu Dec 11, 12:42PM CST
Glancy Binkow & Goldberg LLP reminds investors of Aeterna Zentaris Inc. ("Aeterna" or the "Company" (NASDAQ:AEZS) that purchasers of Aeterna securities between October 18, 2012 and November 5, 2014, inclusive (the "Class Period" , have until January 12, 2015, to file a motion to be appointed as lead plaintiff in the shareholder lawsuit filed in the United States District Court for the District of New Jersey.
AEZS: 0.60 (+0.03)
SHAREHOLDER ALERT: Brower Piven Encourages Investors Who Have Losses in Excess of $100,000 From Investment in Aeterna Zentaris, Inc. to Contact Brower Piven Before the January 12, 2015 Lead Plaintiff Deadline in Class Action Lawsuit -- AEZS
GlobeNewswire - Tue Dec 09, 9:10PM CST
The securities litigation law firm of Brower Piven, A Professional Corporation, announces that a class action lawsuit has been commenced in the United States District Court for the District of New Jersey on behalf of purchasers of Aeterna Zentaris, Inc. ("Aeterna Zentaris" or the "Company" (Nasdaq:AEZS) securities during the period between October 18, 2012 and November 6, 2014, inclusive (the "Class Period" . Investors who wish to become proactively involved in the litigation have until January 12, 2015 to seek appointment as lead plaintiff.
AEZS: 0.60 (+0.03)
Update: My Discussion With RedChip And Thoughts Going Forward
Daniel Ward - at Seeking Alpha - Mon Dec 08, 8:08AM CST
XBI: 183.73 (-0.31), AKER: 3.22 (+0.05), AEZS: 0.60 (+0.03)
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on Their Investment in Aeterna Zentaris, Inc. of Class Action Lawsuit and Upcoming Deadline -- AEZS
GlobeNewswire - Fri Dec 05, 1:40PM CST
Pomerantz LLP has filed a class action lawsuit against Aeterna Zentaris, Inc. ("Aeterna" or the "Company" (Nasdaq:AEZS) and certain of its officers. The class action, filed in United States District Court, District of New Jersey, is on behalf of a class consisting of all persons or entities who purchased Aeterna securities between June 26, 2012 and November 5, 2014, inclusive (the "Class Period" . This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws under the Securities Exchange Act of 1934 (the "Exchange Act" .
AEZS: 0.60 (+0.03)
Cancer Cachexia - Pipeline Review, H2 2014
M2 - Wed Dec 03, 7:39AM CST
Research and Markets (http://www.researchandmarkets.com/research/nngtcd/cancer_cachexia) has announced the addition of the "Cancer Cachexia - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Cancer Cachexia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Cancer Cachexia and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Cancer Cachexia - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Cancer Cachexia pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - Amgen - Eli Lilly and Company - Novartis - Aphios - GTx - Incyte - AEterna Zentaris - Helsinn Healthcare - Radius Health - Vicus Therapeutics - Ohr Pharmaceutical - KAEL-GemVax - RaQualia Pharma - Acacia Pharma - PsiOxus Therapeutics - Signablok - Myomics For more information visit http://www.researchandmarkets.com/research/nn...r_cachexia
RDUS: 26.38 (+1.78), AMGN: 164.53 (-1.55), AEZS: 0.60 (+0.03), OHRP: 8.55 (unch), LLY: 69.55 (-2.06), NVS: 93.52 (-0.82)
Aeterna Zentaris adds to up move
Seeking Alpha - at Seeking Alpha - Tue Dec 02, 12:05PM CST
AEZS: 0.60 (+0.03)
Stock to Watch: AEterna Zentaris Up 16.9% (AEZS)
Comtex SmarTrend(R) - Mon Dec 01, 11:36AM CST
AEterna Zentaris (NASDAQ:AEZS) is one of today's best performing penny stocks, up 16.9% to $0.61 on 1.1x average daily volume. AEterna Zentaris has traded 2.9 million shares thus far today, vs. average volume of 2.8 million shares per day. The stock has outperformed the Dow (16.9% to the Dow's -0.3%) and outperformed the S&P 500 (16.9% to the S&P's -0.7%) during today's trading.
AEZS: 0.60 (+0.03)
Aeterna Zentaris and Sinopharm A-Think Sign Master Collaboration Agreement for Zoptarelin Doxorubicin in China
PR Newswire - Mon Dec 01, 6:30AM CST
All amounts are in U.S. dollars
AEZ.TO: 0.69 (+0.03), AEZS: 0.60 (+0.03)
EQUITY ALERT: Rosen Law Firm Reminds Aeterna Zentaris, Inc. Investors of Important Deadline in Class Action Filed by the Firm -- AEZS
GlobeNewswire - Fri Nov 28, 5:45PM CST
Rosen Law Firm reminds purchasers of Aeterna Zentaris, Inc. securities (Nasdaq:AEZS) between October 18, 2012 and November 6, 2014 of the important January 12, 2015 lead plaintiff deadline in the class action filed by the firm.
AEZS: 0.60 (+0.03)
SHAREHOLDER ALERT: Brower Piven Encourages Investors Who Have Losses In Excess Of $100,000 From Investment In Aeterna Zentaris, Inc. To Contact Brower Piven Before The January 12, 2015 Lead Plaintiff Deadline In Class Action Lawsuit
Business Wire - Tue Nov 25, 5:15PM CST
The securities litigation law firm of Brower Piven, A Professional Corporation, announces that a class action lawsuit has been commenced in the United States District Court for the District of New Jersey on behalf of purchasers of Aeterna Zentaris, Inc. ("Aeterna Zentaris" or the "Company" (Nasdaq: AEZS) securities during the period between October 18, 2012 and November 6, 2014, inclusive (the "Class Period" . Investors who wish to become proactively involved in the litigation have until January 12, 2015 to seek appointment as lead plaintiff.
AEZS: 0.60 (+0.03)
Robbins Arroyo LLP: Aeterna Zentaris Inc. (AEZS) Misled Shareholders According to a Recently Filed Class Action
GlobeNewswire - Tue Nov 25, 5:04PM CST
Shareholder rights law firm Robbins Arroyo LLP announces that an investor of Aeterna Zentaris Inc. (Nasdaq:AEZS) has filed a federal securities fraud class action complaint in the U.S. District Court for the District of New Jersey. The complaint alleges that the company and certain of its officers and directors violated the Securities Exchange Act of 1934 between October 18, 2012 and November 5, 2014. Aeterna Zentaris is a specialty biopharmaceutical company that develops and commercializes novel treatments in oncology and endocrinology.
AEZS: 0.60 (+0.03)
INVESTOR ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses in Excess of $100,000 Investing in Aeterna Zentaris Inc. (AEZS) to Contact the Firm
Marketwired - Fri Nov 21, 7:20PM CST
Faruqi & Faruqi, LLP, a leading national securities law firm, notifies investors of the class action lawsuit filed against Aeterna Zentaris Inc. ("Aeterna" or the "Company" (NASDAQ: AEZS) in the United States District Court for the District of New Jersey.
AEZS: 0.60 (+0.03)
SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action against Aeterna Zentaris, Inc. and Certain Officers -- AEZS
GlobeNewswire - Fri Nov 21, 4:16PM CST
Pomerantz LLP has filed a class action lawsuit against Aeterna Zentaris, Inc. ("Aeterna" or the "Company" (Nasdaq:AEZS) and certain of its officers. The class action, filed in United States District Court, District of New Jersey, is on behalf of a class consisting of all persons or entities who purchased Aeterna securities between June 26, 2012 and November 5, 2014, inclusive (the "Class Period" . This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws under the Securities Exchange Act of 1934 (the "Exchange Act" .
AEZS: 0.60 (+0.03)
SHAREHOLDER ALERT: Class Action Lawsuit Against Aeterna Zentaris Inc. Filed By Glancy Binkow & Goldberg LLP
Business Wire - Fri Nov 21, 11:32AM CST
Glancy Binkow & Goldberg LLP, representing investors of Aeterna Zentaris Inc. ("Aeterna" or the "Company" (NASDAQ:AEZS), has filed a class action lawsuit in the United States District Court for the District of New Jersey on behalf of a class (the "Class" comprising purchasers of Aeterna securities between October 18, 2012 and November 5, 2014, inclusive (the "Class Period" .
AEZS: 0.60 (+0.03)
Aeterna Zentaris Adds Hollings Cancer Center to Multi-National Phase 3 Trial in Endometrial Cancer
PR Newswire - Thu Nov 20, 6:30AM CST
Patient recruitment in line to secure expected interim analysis in H1 2015
AEZ.TO: 0.69 (+0.03), AEZS: 0.60 (+0.03)
Notice of Filing of Securities Fraud Class Action against Aeterna Zentaris Inc. by Abraham, Fruchter & Twersky, LLP
Business Wire - Mon Nov 17, 9:33AM CST
Abraham, Fruchter & Twersky, LLP has filed a securities fraud class action against Aeterna Zentaris Inc. ("Aeterna Zentaris" or the "Company" (NASDAQ:AEZS) and certain of its senior executives in the United States District Court for the District of New Jersey (the "Court" .
AEZS: 0.60 (+0.03)
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Aeterna Zentaris, Inc. - AEZS
PR Newswire - Fri Nov 14, 12:46PM CST
Pomerantz LLP is investigating claims on behalf of investors of Aeterna Zentaris, Inc. ("Aeterna" or the "Company" (NASDAQ: AEZS). Such investors are advised to contact Robert S. Willoughby at rswilloughby@pomlaw.com or 888-476-6529, ext. 237.
AEZS: 0.60 (+0.03)
SHAREHOLDER ALERT: LEVI & KORSINSKY, LLP Notifies Investors of Class Action Against Aeterna Zentaris Inc. and Its Board of Directors and a Lead Plaintiff Deadline of January 12, 2015 -- AEZS
GlobeNewswire - Thu Dec 11, 3:10PM CST
Levi & Korsinsky announces that a class action lawsuit has been commenced in the United States District Court for the District of New Jersey on behalf of investors who purchased Aeterna Zentaris Inc. ("Aeterna Zentaris" or the "Company"
(Nasdaq:AEZS) securities between October 18, 2012 and November 5, 2014. AEZS: 0.60 (+0.03)
INVESTOR ALERT: Glancy Binkow & Goldberg LLP Reminds Investors of the Lead Plaintiff Deadline in the Class Action Lawsuit Against Aeterna Zentaris Inc.
Business Wire - Thu Dec 11, 12:42PM CST
Glancy Binkow & Goldberg LLP reminds investors of Aeterna Zentaris Inc. ("Aeterna" or the "Company"
(NASDAQ:AEZS) that purchasers of Aeterna securities between October 18, 2012 and November 5, 2014, inclusive (the "Class Period" , have until January 12, 2015, to file a motion to be appointed as lead plaintiff in the shareholder lawsuit filed in the United States District Court for the District of New Jersey. AEZS: 0.60 (+0.03)
SHAREHOLDER ALERT: Brower Piven Encourages Investors Who Have Losses in Excess of $100,000 From Investment in Aeterna Zentaris, Inc. to Contact Brower Piven Before the January 12, 2015 Lead Plaintiff Deadline in Class Action Lawsuit -- AEZS
GlobeNewswire - Tue Dec 09, 9:10PM CST
The securities litigation law firm of Brower Piven, A Professional Corporation, announces that a class action lawsuit has been commenced in the United States District Court for the District of New Jersey on behalf of purchasers of Aeterna Zentaris, Inc. ("Aeterna Zentaris" or the "Company"
(Nasdaq:AEZS) securities during the period between October 18, 2012 and November 6, 2014, inclusive (the "Class Period" . Investors who wish to become proactively involved in the litigation have until January 12, 2015 to seek appointment as lead plaintiff. AEZS: 0.60 (+0.03)
Update: My Discussion With RedChip And Thoughts Going Forward
Daniel Ward - at Seeking Alpha - Mon Dec 08, 8:08AM CST
XBI: 183.73 (-0.31), AKER: 3.22 (+0.05), AEZS: 0.60 (+0.03)
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on Their Investment in Aeterna Zentaris, Inc. of Class Action Lawsuit and Upcoming Deadline -- AEZS
GlobeNewswire - Fri Dec 05, 1:40PM CST
Pomerantz LLP has filed a class action lawsuit against Aeterna Zentaris, Inc. ("Aeterna" or the "Company"
(Nasdaq:AEZS) and certain of its officers. The class action, filed in United States District Court, District of New Jersey, is on behalf of a class consisting of all persons or entities who purchased Aeterna securities between June 26, 2012 and November 5, 2014, inclusive (the "Class Period" . This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws under the Securities Exchange Act of 1934 (the "Exchange Act" . AEZS: 0.60 (+0.03)
Cancer Cachexia - Pipeline Review, H2 2014
M2 - Wed Dec 03, 7:39AM CST
Research and Markets (http://www.researchandmarkets.com/research/nngtcd/cancer_cachexia) has announced the addition of the "Cancer Cachexia - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Cancer Cachexia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Cancer Cachexia and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Cancer Cachexia - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Cancer Cachexia pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - Amgen - Eli Lilly and Company - Novartis - Aphios - GTx - Incyte - AEterna Zentaris - Helsinn Healthcare - Radius Health - Vicus Therapeutics - Ohr Pharmaceutical - KAEL-GemVax - RaQualia Pharma - Acacia Pharma - PsiOxus Therapeutics - Signablok - Myomics For more information visit http://www.researchandmarkets.com/research/nn...r_cachexia
RDUS: 26.38 (+1.78), AMGN: 164.53 (-1.55), AEZS: 0.60 (+0.03), OHRP: 8.55 (unch), LLY: 69.55 (-2.06), NVS: 93.52 (-0.82)
Aeterna Zentaris adds to up move
Seeking Alpha - at Seeking Alpha - Tue Dec 02, 12:05PM CST
AEZS: 0.60 (+0.03)
Stock to Watch: AEterna Zentaris Up 16.9% (AEZS)
Comtex SmarTrend(R) - Mon Dec 01, 11:36AM CST
AEterna Zentaris (NASDAQ:AEZS) is one of today's best performing penny stocks, up 16.9% to $0.61 on 1.1x average daily volume. AEterna Zentaris has traded 2.9 million shares thus far today, vs. average volume of 2.8 million shares per day. The stock has outperformed the Dow (16.9% to the Dow's -0.3%) and outperformed the S&P 500 (16.9% to the S&P's -0.7%) during today's trading.
AEZS: 0.60 (+0.03)
Aeterna Zentaris and Sinopharm A-Think Sign Master Collaboration Agreement for Zoptarelin Doxorubicin in China
PR Newswire - Mon Dec 01, 6:30AM CST
All amounts are in U.S. dollars
AEZ.TO: 0.69 (+0.03), AEZS: 0.60 (+0.03)
EQUITY ALERT: Rosen Law Firm Reminds Aeterna Zentaris, Inc. Investors of Important Deadline in Class Action Filed by the Firm -- AEZS
GlobeNewswire - Fri Nov 28, 5:45PM CST
Rosen Law Firm reminds purchasers of Aeterna Zentaris, Inc. securities (Nasdaq:AEZS) between October 18, 2012 and November 6, 2014 of the important January 12, 2015 lead plaintiff deadline in the class action filed by the firm.
AEZS: 0.60 (+0.03)
SHAREHOLDER ALERT: Brower Piven Encourages Investors Who Have Losses In Excess Of $100,000 From Investment In Aeterna Zentaris, Inc. To Contact Brower Piven Before The January 12, 2015 Lead Plaintiff Deadline In Class Action Lawsuit
Business Wire - Tue Nov 25, 5:15PM CST
The securities litigation law firm of Brower Piven, A Professional Corporation, announces that a class action lawsuit has been commenced in the United States District Court for the District of New Jersey on behalf of purchasers of Aeterna Zentaris, Inc. ("Aeterna Zentaris" or the "Company"
(Nasdaq: AEZS) securities during the period between October 18, 2012 and November 6, 2014, inclusive (the "Class Period" . Investors who wish to become proactively involved in the litigation have until January 12, 2015 to seek appointment as lead plaintiff. AEZS: 0.60 (+0.03)
Robbins Arroyo LLP: Aeterna Zentaris Inc. (AEZS) Misled Shareholders According to a Recently Filed Class Action
GlobeNewswire - Tue Nov 25, 5:04PM CST
Shareholder rights law firm Robbins Arroyo LLP announces that an investor of Aeterna Zentaris Inc. (Nasdaq:AEZS) has filed a federal securities fraud class action complaint in the U.S. District Court for the District of New Jersey. The complaint alleges that the company and certain of its officers and directors violated the Securities Exchange Act of 1934 between October 18, 2012 and November 5, 2014. Aeterna Zentaris is a specialty biopharmaceutical company that develops and commercializes novel treatments in oncology and endocrinology.
AEZS: 0.60 (+0.03)
INVESTOR ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses in Excess of $100,000 Investing in Aeterna Zentaris Inc. (AEZS) to Contact the Firm
Marketwired - Fri Nov 21, 7:20PM CST
Faruqi & Faruqi, LLP, a leading national securities law firm, notifies investors of the class action lawsuit filed against Aeterna Zentaris Inc. ("Aeterna" or the "Company"
(NASDAQ: AEZS) in the United States District Court for the District of New Jersey. AEZS: 0.60 (+0.03)
SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action against Aeterna Zentaris, Inc. and Certain Officers -- AEZS
GlobeNewswire - Fri Nov 21, 4:16PM CST
Pomerantz LLP has filed a class action lawsuit against Aeterna Zentaris, Inc. ("Aeterna" or the "Company"
(Nasdaq:AEZS) and certain of its officers. The class action, filed in United States District Court, District of New Jersey, is on behalf of a class consisting of all persons or entities who purchased Aeterna securities between June 26, 2012 and November 5, 2014, inclusive (the "Class Period" . This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws under the Securities Exchange Act of 1934 (the "Exchange Act" . AEZS: 0.60 (+0.03)
SHAREHOLDER ALERT: Class Action Lawsuit Against Aeterna Zentaris Inc. Filed By Glancy Binkow & Goldberg LLP
Business Wire - Fri Nov 21, 11:32AM CST
Glancy Binkow & Goldberg LLP, representing investors of Aeterna Zentaris Inc. ("Aeterna" or the "Company"
(NASDAQ:AEZS), has filed a class action lawsuit in the United States District Court for the District of New Jersey on behalf of a class (the "Class" comprising purchasers of Aeterna securities between October 18, 2012 and November 5, 2014, inclusive (the "Class Period" . AEZS: 0.60 (+0.03)
Aeterna Zentaris Adds Hollings Cancer Center to Multi-National Phase 3 Trial in Endometrial Cancer
PR Newswire - Thu Nov 20, 6:30AM CST
Patient recruitment in line to secure expected interim analysis in H1 2015
AEZ.TO: 0.69 (+0.03), AEZS: 0.60 (+0.03)
Notice of Filing of Securities Fraud Class Action against Aeterna Zentaris Inc. by Abraham, Fruchter & Twersky, LLP
Business Wire - Mon Nov 17, 9:33AM CST
Abraham, Fruchter & Twersky, LLP has filed a securities fraud class action against Aeterna Zentaris Inc. ("Aeterna Zentaris" or the "Company"
(NASDAQ:AEZS) and certain of its senior executives in the United States District Court for the District of New Jersey (the "Court" . AEZS: 0.60 (+0.03)
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Aeterna Zentaris, Inc. - AEZS
PR Newswire - Fri Nov 14, 12:46PM CST
Pomerantz LLP is investigating claims on behalf of investors of Aeterna Zentaris, Inc. ("Aeterna" or the "Company"
(NASDAQ: AEZS). Such investors are advised to contact Robert S. Willoughby at rswilloughby@pomlaw.com or 888-476-6529, ext. 237. AEZS: 0.60 (+0.03)
